The journey from researchlab to selling an innovation is often long and unpredictable. Rennie Whang speaks to Dr Namyong Kim, chief executive of A*Star spin-off Curiox Biosystems, about the ups and downs it encountered.
Q What does Curiox Biosystems do?
A We have developed a system for biomedical research that miniaturises biological assays using cells and proteins.
By reducing the size of the assay used in experiments to find out biological phenomena or develop drugs, scientists need fewer samples and biological reagents. This helps speed up the development process. Current assays have issues with sensitivity and reproducibility, along with high cost. The DropArray system improves on these parameters